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Objective Increasing concern over bacterial resistance to cotrimoxazole, which is recommended by WHO as a ﬁrst-line drug for 
treating non-severe pneumonia, led to the suggestion that this might not be optimal therapy. However, changing to alternative 
antimicrobial agents, such as amoxicillin, is costly. We compared the clinical efﬁcacy of twice-daily cotrimoxazole in standard versus 
double dosage for treating non-severe pneumonia in children.
Methods A randomized controlled multicentre trial was implemented in seven hospital outpatient departments and two community 
health programmes. A total of 1143 children aged 2–59 months with non-severe pneumonia were randomly allocated to receive 
4 mg trimethoprim plus 20 mg sulfamethoxazole/kg of body weight or 8 mg trimethoprim plus 40 mg sulfamethoxazole/kg of body 
weight orally twice-daily for 5 days Treatment failure occurred when a child required a change of therapy, died or was lost to follow-up. 
Children required a change of therapy if their condition worsened (they developed chest indrawing or danger signs) or if at 48 hours 
after enrolment, their clinical condition was the same (deﬁned as having a respiratory rate that was 5 breaths/minute higher or lower 
than at the time of enrolment).
Findings The results of 1134 children were analysed: 578 were assigned to the standard dose of cotrimoxazole and 556 to the double 
dose. Treatment failed in 112 children (19.4%) in the standard group and 118 (21.2%) in the double-dose group (relative risk 1.10; 
95% conﬁdence interval = 0.87–1.37). Using multivariate analysis we found that treatment was more likely to fail in children who 
were not given the medicine correctly (P = 0.001), in those younger than 12 months (P = 0.004), those who had used antibiotics 
previously (P = 0.002), those whose respiratory rate was  20 breaths/minute above the age-speciﬁc cut-off point (P = 0.006), 
and those from urban areas (P = 0.042).
Conclusion Both standard and double strength cotrimoxazole were equally effective in treating non-severe pneumonia. Close follow-
up of patients is essential to prevent worsening of disease. Deﬁnitions of clinical failure need to be more speciﬁc. Surveillance in both 
rural and urban areas is essential in the development of treatment policies that are based on clinical outcomes.
Keywords Trimethoprim-sulfamethoxazole combination/administration and dosage/therapeutic use; Pneumonia, Bacterial/drug therapy; 
Treatment failure; Child; Randomized controlled trials; Multicenter studies; Pakistan (source: MeSH, NLM).
Mots clés Triméthoprime-sulfaméthoxazole, Association/administration et posologie/usage thérapeutique; Pneumonie bactérienne/
chimiothérapie; Echec thérapeutique; Enfant; Essai clinique randomisé; Etude multicentrique; Pakistan (source: MeSH, INSERM).
Palabras clave Combinación trimetoprim-sulfametoxazol/administración y dosiﬁcación/uso terapéutico; Neumonía bacteriana/
quimioterapia; Insuﬁciencia del tratamiento; Niño; Ensayos controlados aleatorios; Estudios multicéntricos; Pakistán (fuente: DeCS, 
BIREME).
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Introduction
WHO estimates that 1.9 million deaths occur every year from 
lower respiratory infections, primarily pneumonia, mostly in 
developing countries (1). Because Streptococcus pneumoniae and 
Haemophilus inﬂuenzae are the most common causes of child-
hood bacterial pneumonia in developing countries, WHO, using 
standardized case management guidelines, recommends using 
oral cotrimoxazole or amoxicillin to treat non-severe pneumo-
nia at ﬁrst-level health facilities (2, 3).
Pneumonia is a leading cause of death among children in 
Pakistan. In 1989, the Government of Pakistan adopted WHO’s 
recommendation to use oral cotrimoxazole as ﬁrst-line out-
patient treatment for non-severe pneumonia because of its cost, 
twice-daily dosage schedule, efﬁcacy and wide availability (4). 
While high rates of resistance in nasopharyngeal and blood iso-
lates were documented from 1986 to 1994 (5–8), studies in the 
early 1990s showed that cotrimoxazole was effective in treat-
ing more than 90% of children who had community-acquired 
pneumonia (9, 10). A 1991–92 hospital-based study found no 
difference in clinical efﬁcacy between twice-daily cotrimoxazole 
and thrice-daily amoxicillin for treating non-severe pneumonia 
(failure rates of 13% and 12%, respectively) (11).
Changing from cotrimoxazole to amoxicillin would cost 
an estimated US$ 25 million yearly in Pakistan, a signiﬁcant 
proportion of the national health budget (12). Due to the faster 
elimination of one component of cotrimoxazole (trimethoprim) 
in young children, higher doses are needed to achieve plasma 
concentrations comparable to those observed in adults, leading 
to the suggestion that the daily dose of trimethoprim should 
be increased by 100% for younger children (13). We evaluated 
the clinical effectiveness of cotrimoxazole in standard versus 
double doses to treat children with non-severe pneumonia.
Methods
Patients
We conducted a randomized controlled double-blind multi-
centre trial in seven urban and two rural sites, one with dis-
persed health centres (Table 1). Children were seen in hospital 
outpatient or community clinics. Free and informed consent 
was obtained from children’s parents; procedures followed for 
obtaining consent were in accordance with the ethical standards 
of the Declaration of Helsinki (14). The National ARI Control 
Programme in Pakistan approved the study.
Children aged 2–59 months presenting with cough and 
difﬁcult or fast breathing (tachypnoea) were assessed using the 
standard WHO acute respiratory infection (ARI) algorithm, 
which has been shown to have a sensitivity and speciﬁcity of 
80% for the diagnosis of pneumonia (2, 3). Children were 
classiﬁed as having non-severe pneumonia if their respiratory 
rate was  50 breaths per minute and they were aged 2–11 
months and if their respiratory rate was  40 breaths per min-
ute if they were aged 12–59 months. Children were classiﬁed as 
having severe pneumonia if they had lower chest wall indrawing 
(with or without tachypnoea); they were classiﬁed as having 
very severe disease if one or more danger signs were present 
(convulsions, drowsiness, inability to drink, stridor in a calm 
child, and clinically severe malnutrition).
The respiratory rate used for assessment was the average 
of two readings taken for 1 minute each when the child was 
quiet, feeding or asleep. Children who were wheezing received 
nebulized or inhaled salbutamol and were reassessed for tachy-
pnoea after 30 minutes. Febrile children received paracetamol.
Children with non-severe pneumonia constituted our 
study population. Excluded were children with severe pneumo-
nia, very severe disease, stridor, acute nonpulmonary or under-
lying chronic illness (including asthma, which was deﬁned as a 
history of wheezing  3 times if wheezing was present at the 
current evaluation), history of cotrimoxazole allergy, adminis-
tration of WHO-recommended antimicrobials in appropriate 
doses during the previous 48 hours, or if the parents declined 
to participate. Children with severe malnutrition were excluded 
because WHO recommends they be referred to secondary care 
facilities for inpatient therapy (2). To ensure follow-up, at home 
if needed, only children living within the municipal limits of 
urban sites and walking distance (< 5 km) of the clinic in rural 
sites were enrolled.
A senior clinician supervised the study at every site. In 
urban sites, study physicians collected data. In rural sites, “lady 
health visitors” (a recognized category of paramedical workers in 
Pakistan) collected data under the supervision of a study physi-
cian. Study personnel were trained in standard ARI case manage-
ment and study methodology at the coordinating centre, the 
Children’s Hospital in Islamabad; at rural sites, study personnel 
trained the lady health visitors assigned to peripheral health 
centres. The study coordinator visited every site.
A randomization scheme for 200 patients was generated 
for each site using a computer program that allocated patients to 
uneven blocks of two, four and six patients. To cater for children 
of different weights, two bottles of medicine were prepared for 
each code. Each site received an equal number of each strength 
of cotrimoxazole packaged in identical bottles with the same 
appearance and taste: standard strength (200 mg sulfamethoxa-
zole plus 40 mg trimethoprim per 5 ml suspension) and double 
strength (400 mg sulfamethoxazole plus 80 mg trimethoprim 
per 5 ml suspension). The randomization list with unique identi-
ﬁcation numbers was kept by the company preparing the cotri-
moxazole and a health professional who randomly allocated the 
drugs but who was not involved in study implementation. Drug 
assignment was concealed from parents and study personnel. 
The code was broken after primary analysis of the data.
Data were not collected on all children eligible for enrol-
ment, however, efforts were made to recruit as many children as 
possible. Children meeting entry criteria were enrolled by study 
personnel and randomly allocated, after informed witnessed 
verbal consent was obtained, to receive a uniquely coded set of 
two bottles containing the same strength of cotrimoxazole to be 
given twice daily for ﬁve days: 4 mg trimethoprim plus 20 mg 
sulfamethoxazole per kg of body weight (standard dose) or 8 mg 
(double dose) trimethoprim plus 40 mg sulfamethoxazole per 
kg of body weight.
All mothers received standard ARI home management 
instructions (feed the child, increase the intake of ﬂuids, soothe 
the throat and relieve cough with safe local remedies, such as 
honey water or green tea) that emphasized they should watch for 
worsening symptoms (chest indrawing or other danger signs) 
and that they should bring the child in at any time if they had 
concerns. The proper dose and frequency and duration of ad-
ministration of the drug were carefully explained. Compliance 
was evaluated at each follow-up visit. Children were considered 
to have been receiving the correct dose if the mother reported 
giving the prescribed dose; bottles were checked to estimate if 
80% of the required dose had been given.
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Table 1. Characteristics of 1134 children with non-severe pneumonia enrolled in study of standard dose versus double dose 
treatment with cotrimoxazole, by treatment group
Characteristics Treatment group
  Standard dose (n = 578) Double dose (n = 556)
Site of enrolmenta  
Abbottabad 16  (2.8)b 13  (2.3)
Gilgit (Oshikandass village, rural) 76  (13.1) 74  (13.3)
Gilgit (rural, dispersed centres in periphery) 56  (9.7) 49  (8.8)
Islamabad 88  (15.2)  84  (15.1)
Karachi 74  (12.8) 69  (12.4)
Lahore 28  (4.8) 39  (7.0)
Multan 100  (17.3) 99  (17.8)
Peshawar 99  (17.1) 100  (18.0)
Quetta 41  (7.1) 29  (5.2)
Urban  446  (77.2) 433  (77.9)
Agec 11  (5–21) 11  (5-21)
2–11 months 297  (51.4) 280  (50.4)
12–59 months 281  (48.6) 276  (49.6)
Male 369  (63.8) 330  (59.4)
History at baseline  
No. of days ill prior to presentationc 3  (2–5) 3  (2–5)
Fever 511  (88.4) 491  (88.3)
Cough 552  (95.5) 531  (95.5)
Difﬁculty breathing 313  (54.2) 319  (57.4)
Tight chest binding  8  (1.4) 8  (1.4)
Documented antibiotic use in past 7 daysd 20  (3.5) 28  (5.0)
Wheezing  3 times at any time in the past  23  (4.0) 22  (4.0)
Vomiting 152  (26.3) 148  (26.6)
Diarrhoea 97  (16.8) 104  (18.7)
Current breastfeedinge  
Age 2–11 months  257  (44.5) 238  (42.8)
Age 12–23 months  105  (18.2) 93  (16.7)
Examination at baseline  
Respiratory ratec  
   2–11 months 58.0  (54.5–62.0) 59.0  (55.5–63.0)
   12–59 months 50.0  (46.0–55.5) 50.0  (45.0–54.0)
High respiratory ratef 54 (9.3) 63  (11.3)
Wheezing 149  (25.8) 144  (25.9)
   2–11 months 103  (34.7) 79  (28.2)
   12–59 months 46  (16.4) 65  (23.6)
Malnourishedg 88  (15.3)h 87  (15.7) i
Weight-for-age scorec -0.82  (-1.64 – -0.11) -0.90  (-1.67 – 0.03)
During the study  
Was not given medicine correctly 33  (5.7) 31  (5.6)
Wheezing at any time after enrolment 159  (27.5) 157  (28.2)
a  As deﬁned by the local government urban areas have > 5000 inhabitants, educational and health facilities, infrastructure, a post ofﬁce and are areas where  
 most of the population works in nonagricultural sectors. Rural areas are those that have  5000 inhabitants and where the majority of the population works in  
 agriculture.
b  Values in parentheses are percentages unless otherwise indicated.
c  Values are medians (interquartile range).
d  Assessed by either the presence of a prescription, presence of a medicine bottle or parent or caretaker knowing the name of the antibiotic.
e  18 children  2 years old in the group receiving the standard dose and 20 in the group receiving the double dose were being breastfed.
f  A high respiratory rate was one in which the child had  20 breaths/minute above the age-adjusted WHO threshold for tachypnoea, that is  70 for children  
 aged 2–11 months and  60 for those aged 12–59 months.
g  Weight-for-age scores > 2 standard deviations below normal (15).
h  n = 575.
i  n = 553. 
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After enrolment (day 0), children were reassessed on day 
2 and day 5, and if they had not been receiving the correct dose 
or if therapy was changed (see below) they were also seen on day 
7; examination was generally done by the same person. Children 
not presenting for scheduled follow-up visits were assessed at 
home the next day, or if they were unable to be traced they were 
considered lost to follow-up. At follow-up visits, clinical assess-
ment was based on the mother’s opinion of the child’s condition 
and the health worker’s assessment. Children were considered to 
have improved if they had a slower respiratory rate (either within 
the normal range for their age, or > 5 breaths/minute lower than 
at the time of the previous evaluation); they were considered to 
be the same if there was persistent tachypnoea (their respiratory 
rate was 5 breaths/minute higher or lower than at the time of 
previous evaluation) without chest indrawing or danger signs. 
A child’s condition was considered to have worsened if he or she 
had developed severe pneumonia or very severe disease. Patients 
whose condition worsened were referred for inpatient parenteral 
treatment with benzylpenicillin, ampicillin or chloramphenicol. 
If parenteral therapy could not be given, oral chloramphenicol 
(25 mg/kg every 6 hours) was prescribed.
Children whose condition had improved on day 2 con-
tinued cotrimoxazole until day 5, or if they had not been given 
the medicine as prescribed they continued until day 7. If a child 
had been given the drug correctly and his or her condition 
was considered to be the same on day 2 or day 5, therapy was 
changed to oral amoxicillin (15 mg/kg every 8 hours). Children 
who had not been given their medicine correctly and whose 
condition was the same on day 2 continued with cotrimoxazole 
for 2 more days and were then reassessed; if their condition re-
mained the same, the drug was changed to amoxicillin. Children 
whose treatment was changed to amoxicillin were re-evaluated 
every 48–72 hours after changing medication until cured. Chil-
dren who did not improve after 48 hours on amoxicillin were 
referred for parenteral therapy.
Clinical cure was deﬁned as improvement with return of 
respiratory rate to the age-speciﬁc normal range. The primary 
outcomes were deﬁned as treatment success (resolution on co-
trimoxazole) and treatment failure (change of therapy, death or 
loss to follow-up).
Statistical analysis
The sample size was calculated to show a 5% difference in 
treatment outcomes between children receiving standard dose 
and those receiving double dose cotrimoxazole. Our hypothesis 
was that the failure rate would be lower with the double dose 
of cotrimoxazole (5%) than with the standard dose (10%) (9, 
10). With α = 0.05 and a power of 80%, a sample size of 474 
children in each group was needed.
Data were recorded on autocopy data forms, one of which 
was kept on-site and one of which was sent to the coordinating 
centre. Double data entry was performed at two sites (Children’s 
Hospital, Islamabad, and Aga Khan Health Service, Gilgit) 
and validated using Epi Info software version 6, (Centers for 
Disease Control and Prevention, Atlanta, GA, USA). The range 
and internal consistency of the data were checked. Analysis was 
carried out using Epi Info and the SPSS software package ver-
sion 10 (SPSS Inc., Chicago, IL, USA).
Baseline characteristics of the two treatment groups were 
compared. Outcomes for the groups were compared using an 
estimation of relative risk with 95% conﬁdence intervals (CIs). 
Data were compared for the treatment success and treatment 
failure groups. Univariate analysis of categorical variables in-
cluded estimates of relative risks and 95% CIs and the Student’s 
t-test for continuous variables; for the t-test, only P-values are 
reported.
Multivariate logistic regression analysis was carried out to 
identify the determinants of treatment failure. In all analyses 
the treatment group indicator was retained to reﬂect the origi-
nal design of the study. To ensure our results were relevant to 
the management of pneumonia at the programme level, we 
categorized some continuous variables, such as age, duration 
of illness and respiratory rate, for logistic regression analysis. 
Malnutrition was deﬁned as weight-for-age scores that were 
>2 standard deviations below normal (15).
Findings
Between October 1995 and July 1996, 1143 children were 
enrolled in the study. The analysis of the primary outcome 
involved 1134/1143 patients, excluding 8 who were incorrectly 
enrolled and 1 who did not received the allocated intervention. 
After excluding these 9 cases of protocol violation, 578 chil-
dren received the standard dose and 556 received the double 
dose of cotrimoxazole (Fig. 1). Thus these children received 
the intended treatment and their results were analysed for the 
primary outcome measure.
The median age of the children was 11 months (interquar-
tile range = 5–21 months); 577 children (50.9%) were younger 
than 12 months old. Baseline and intrastudy characteristics are 
presented in Table 1. At enrolment, wheeze was more frequent 
in children aged < 12 months of age (182/577; 31.5%) than in 
older children (111/557; 19.9%) (relative risk (RR) 1.58; 95% 
CI = 1.29–1.94).
Treatment failure occurred in 230 children (20.3%) 
(Fig. 1). Clinical success was similar in the standard dose and 
double dose groups: 466 children in standard dose group 
(80.6%) and 438 in the double dose group (78.8%) (RR = 1.10; 
95% CI = 0.87–1.37). A total of 32 children (2.8%) were lost to 
follow-up. In the standard dose group, drug treatment was with-
drawn in 5 children because of rash (0.7%); it was withdrawn 
from 1 child (0.2%) in the double dose group. The difference 
was not signiﬁcant (RR = 3.85; 95% CI = 0.43–34.32). No 
serious side-effects occurred.
Of the 198 children requiring a change of therapy 
(Fig. 2), 161 (81.3%) were cured on amoxicillin, 1 (0.5%) 
was cured with chloramphenicol, 24 (12.1%) on parenteral 
antibiotics, 1 died (3-month-old hospitalized male with very 
severe disease), and the ﬁnal outcome of 11 children (5.5%) 
was unknown. Of these 11, 7 were referred to hospital; 3 had 
had their drug changed to amoxicillin; and 1 had cotrimoxa-
zole stopped due to rash. Three had improved at the time of 
their last follow-up.
On day 2, 910/1134 children (80.2%) were classiﬁed as 
improved; 133 (11.7%) were the same; and 68 (6.0%) were 
worse. Altogether 23 children (2.0%) were not seen (18 lost 
to follow-up, 5 cured on cotrimoxazole). There was no signiﬁ-
cant difference between the two treatment groups among the 
children at the ﬁrst follow-up visit. Of 68 whose condition 
deteriorated, 41 developed severe pneumonia and 27 developed 
very severe disease (Fig. 2). Of the 910 children who improved, 
33 subsequently required a change of therapy. Of the 133 who 
remained the same, the drug treatment was changed according 
to protocol in 87 but not changed according to protocol in 46; 
35 of these 46 children (76.0%) recovered on cotrimoxazole.
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4 treatment failures
Fig. 1. Flowchart showing how patients proceeded through the study
WHO 04.144
1143 children randomizeda
a Uniform information on all eligible patients is not available.
b 3 children did not have pneumonia and 1 with age unspecified; all cured after 5 days of cotrimoxazole treatment.
c 2 children without pneumonia, 1 with severe pneumonia, 1 with severe malnutrition; first 3 cured after 5 days of cotrimoxazole treatment.
Treatment failed for last child who required parenteral therapy for cure.
d Includes 1 death.
583 allocated
standard dose
cotrimoxazole
5 excluded
4 enrolled incorrectlyb
1 received bottle with
two codes and drug strengths
560 allocated
double dose
cotrimoxazole
4 excluded
All enrolled incorrectlyc
578 analysed 556 analysed
91 treatment failures
(9 lost to follow-up)
First follow-up
(Day 2)
87 treatment failures
(9 lost to follow-up)
487 continued treatment 469 continued treatment
17 treatment failures
(1 died)
(7 lost to follow-up)
Second follow-up
(Day 5)
29 treatment failures
(7 lost to follow-up)
446 clinically cured 24 continued treatment 28 continued treatment 412 clinically cured
4 treatment failures 2 treatment failuresThird follow-up
(Day 7)
20 clinically cured 26 clinically cured
Clinically cured
Treatment failures
Change in therapyd
Lost to follow-up
466 (80.6%)
112 (19.4%)
96 (16.6%)
16 (2.8%)
438 (78.8%)
118 (21.2%)
102 (18.3%)
16 (2.9%)
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Fig. 2. Treatment details for the 198/1134 children treated with single dose or double dose cotrimoxazole who needed a change
in treatment for non-severe pneumonia
WHO 04.145
a Includes 1 death.
b 1 not given medicine correctly; protocol for changing medicine not followed in 9 children.
c Includes 1 child who developed rash.
d 3 children developed rash, 1 still had fast breathing. Drug changed on clinical grounds.
e Child developed rash.
f 1 child became worse before scheduled second follow-up and medicine was changed.
g Child still appeared sick and had high respiratory rate.
h 1 not given medicine correctly; protocol for changing medicine not followed in 2 children.
Children needing
to change treatment
(n = 198)
Condition the same
(pneumonia)
(n = 97)
Condition worse (n = 68)a
Severe pneumonia (n = 41)
Very severe disease (n = 27)
Condition improving (n = 33)
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Medicine changed Medicine continued
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Fifty-seven children whose condition should have been 
classiﬁed as being the same at their ﬁrst follow-up visit were 
considered to have improved and therapy was not changed; 
53 of these children (93.0%) recovered on cotrimoxazole. Of 
the 103 children (46 + 57) who should have had their therapy 
changed but did not, 85% recovered on cotrimoxazole. Half 
of these 103 children had a decrease in their respiratory rate 
of 3–5 breaths/minute.
A total of 1070/1134 (94.3%) children received the cor-
rect dose of medicine for the correct length of time. There were 
2337 follow-up visits, of which 16% were at home; medicine 
bottles were checked at 92% of visits.
When the treatment groups were combined, univariate 
analysis showed that children were at a greater risk of treatment 
failure if at enrolment they were < 12 months of age, had had 
a longer duration of illness, had used antibiotics in the previ-
ous 7 days, had a high respiratory rate ( 20 breaths/minute 
above the age-speciﬁc cut-off point), had a history of tight 
chest-binding (the practice of wrapping a child’s chest tightly 
with cloth, which in some areas of the country is thought to 
be therapeutic), and lived in urban centres (Table 2, available 
only on the web version at http://www.who.int/bulletin). Also 
at higher risk of treatment failure were children who were not 
given the medicine correctly or who had wheezing at any time 
after enrolment.
Logistic regression modelling was used to adjust for pos-
sible confounding and interaction effects (Table 3). In the best 
multivariate model the following variables were signiﬁcantly 
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associated with treatment failure although strength of cotri-
moxazole was not: age < 12 months, high respiratory rate at 
enrolment, previous antibiotic use, urban status and treatment 
not given correctly.
The failure rate was 14.9% (38/255) in the two rural areas 
compared with 21.8% (192/879) in the urban areas (RR = 0.68; 
95% CI = 0.50–0.94) when both treatment groups were com-
bined. The lowest failure rate (10/105, 9.5%) was in a rural pro-
gramme that had many dispersed health centres. Children from 
urban centres were more likely to be younger and better nour-
ished, present later in the course of their illness, have a history 
of antibiotic use as well as have a cough, difﬁculty breathing, 
vomiting, and wheeze at any time after enrolment (Table 4, 
available only on the web version at http://www.who.int/bulletin). 
They were less likely to have a history of asthma and more likely 
to have been given their medicine correctly.
Discussion
Clinical efﬁcacy of cotrimoxazole
The results show that there was no signiﬁcant difference be-
tween the clinical efﬁcacy of the standard dose of cotrimoxazole 
and the double dose when given twice daily to treat children 
with non-severe pneumonia. As in two other studies (16, 17), 
the clinical failure rate was comparatively high; however, in this 
study follow-up was good (and it was also very good in the 
other two studies cited), and almost all children with non-severe 
pneumonia for whom treatment failed were cured when given 
amoxicillin. Few children required parenteral therapy.
The failure rate of cotrimoxazole in this study is higher 
than the 9% reported in community-based studies (9, 10) and 
the 13% reported in a hospital-based study (11) from the early 
1990s, but it is similar to the failure rate from a later study (16). 
These differences could be due to temporal changes or to differ-
ences in the deﬁnition of failure. It is critical to have a standard-
ized deﬁnition of clinical failure to detect trends over time. If 
failure rates are increasing then other antimicrobial regimens for 
treating non-severe pneumonia need to be explored. Repeating 
this study in other countries that have had similar failure rates 
with cotrimoxazole would be useful in conﬁrming the gener-
alizability of our results.
Table 3. Multivariate analysis of predictors of therapy failure 
among 1134 children treated for non-severe pneumonia 
with either standard dose or double dose cotrimoxazole
Variable Adjusted P-value 
 relative riska
Age < 12 months 1.42  (1.11–1.79) 0.005
Antibiotic use in past 7 days 1.96  (1.29–2.74) 0.003
High respiratory rate at baselineb 1.58  (1.14–2.10) 0.007
Living in urban area at baseline  1.39  (1.00–1.87) 0.047
Child not given medicine correctly 2.00  (1.37–2.70) 0.001
Strength of cotrimoxazole 1.07  (0.84-1.34) 0.588
Wheezing any time after  1.24  (0.96-1.58) 0.094 
 enrollment
a  Values in parentheses are 95% conﬁdence intervals.
b  A high respiratory rate was one in which the child had  20 breaths/ 
 minute above the age-adjusted WHO threshold for tachypnoea, that is  70  
 for children aged 2–11 months and  60 for those aged 12–59 months.
As in previous studies (11, 16, 17), we found that treat-
ment failure was signiﬁcantly associated with younger age, high 
initial respiratory rate and not being given the treatment cor-
rectly. We identiﬁed new risk factors of previous antibiotic use 
and living in an urban area. Children with these risk factors thus 
require special attention and counselling.
The high treatment failure rate could have been caused 
by: increasing resistance of S. pneumoniae and H. inﬂuenzae to 
cotrimoxazole, viral etiology, a high incidence of underlying 
hyperactive airway disease, and/or our use of sensitive criteria 
to assess therapy failure. We have previously discussed the ﬁrst 
three factors (15). In this study, children who had already used 
antibiotics were twice as likely to be failed by treatment, sug-
gesting that their infection could be due to resistant bacteria.
Deﬁnition of therapy failure
The deﬁnition of therapy failure was sensitive: children whose 
condition was considered to be the same on day 2 had a change 
in therapy and were classiﬁed as having had treatment failure. 
To be classiﬁed as improved on day 2, children had to have a 
decrease in their respiratory rate of > 5 breaths/minute. WHO 
guidelines for improvement are “slower breathing, less fever, 
eating better” (2, 3); these are nonspeciﬁc and could be clari-
ﬁed further. If we had deﬁned improvement as a decrease in 
respiratory rate of > 3 or 4 breaths/minute, it is possible that 
the failure rate would be lower. Notably, of the 103 children 
who according to the respiratory criteria on day 2 should have 
had their drug changed but did not, 85% recovered. They may 
have been “slow responders” to therapy or had viral infections 
or hyperactive airway disease. If a similar proportion of the 87 
children whose condition was classiﬁed as being the same on 
day 2 and who had a change in therapy had also recovered with-
out therapy change, then our failure rate would have been only 
13.8%. Further work is required to improve the speciﬁcity of 
criteria for clinical failure, perhaps by more closely monitoring 
children whose condition is the same on day 2 for up to 5–7 
days in order to determine indicators of subsequent worsening.
We found WHO ARI case management guidelines use-
ful. Re-evaluation at day 2 was appropriate since 68/76 (89.4%) 
of those who became worse were detected on day 2. In total, 
80% of children requiring a change of therapy responded well to 
oral amoxicillin. Counselling and follow-up after 2 days resulted 
in a minimal loss to follow-up.
Urban areas versus rural areas
Living in an urban area was a risk factor for failure. The low 
failure rate among rural children, as found in other community 
studies (9, 10, 18), emphasizes the need to conduct periodic 
surveillance of clinical effectiveness in rural areas especially since 
the majority of Pakistan’s population (19), and that in many 
other developing countries, lives in rural areas. Most policies 
on managing childhood illnesses are based on data from urban 
settings often because the inclusion of rural areas is logistically 
difﬁcult. If rural areas are consistently found to have lower rates 
of failure, a ﬂexible treatment policy that speciﬁes distinct ﬁrst-
line therapies for rural and urban areas may be necessary.
Limitations and strengths
The study would have been more generalizable if all children 
had been treated according to the protocol; however, this did 
not materially affect our conclusions. The study design would 
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have been improved by including a control group treated with 
amoxicillin but for reasons of cost (amoxicillin treatment would 
have cost four times more than cotrimoxazole treatment) and 
sample size (we would have needed to recruit about 600 more 
children), we could not do this. The study would have been 
more complicated if amoxicillin was given three times daily, 
and adding a third (placebo) dose to the cotrimoxazole group 
may have resulted in decreased compliance in the cotrimoxazole 
groups. However, in two subsequent studies (16, 17), clinical 
response to amoxicillin has been similar to that found with 
cotrimoxazole. These studies were done in similar sites in Paki-
stan at the same time of year with comparable populations. We 
would expect the etiological agents for community-acquired 
pneumonia (bacterial being primarily S. pneumoniae and H. 
inﬂuenzae) to have been the same in all three studies, as has been 
determined in other studies in Pakistan (7, 11, 20) and in other 
developing countries (3).
Other limitations of our study include the lack of micro-
biological data, chest radiographs, detailed clinical examination 
and a longer follow-up period. Given the high incidence of 
pneumonia in the community in low-resource settings, it is 
impractical and expensive to obtain chest radiographs and do 
pulse oximetry, blood cultures or lung punctures in all children 
with suspected pneumonia. Even if, as part of the study, standard 
investigations were obtained for all patients, it would not have 
been possible to generalize the results to other low-resource set-
tings, where pneumonia is not diagnosed using these methods. 
The intention of this study was to use the WHO ARI guidelines, 
which do not recommend such investigations for diagnosing 
pneumonia in the ﬁeld.
The strengths of our study include the good follow-up 
rates, high rates of compliance with treatment, low mortality, 
inclusion of paramedical workers and of urban and rural sites 
in different geographical areas of the country. Our ﬁnding that 
with intermittent supervision paramedical workers in rural areas 
could successfully evaluate patients suggests that such workers 
can be used to assess the clinical effectiveness of pneumonia 
therapy, as has successfully been done elsewhere (18).
Conclusion
Children’s outcomes were not improved by doubling the dose 
of cotrimoxazole to treat non-severe childhood pneumonia. 
Because another study has identiﬁed similar failure rates with 
a shorter course of a more expensive drug (3–5 days of amoxi-
cillin) (17), we recommend testing the effectiveness of 3 days 
of treatment with cotrimoxazole in children with non-severe 
pneumonia. Periodic surveillance of the clinical effectiveness 
of cotrimoxazole in both urban and rural areas is important in 
guiding decisions on optimal ﬁrst-line therapy for non-severe 
pneumonia. Further work is required to increase the speciﬁcity 
of the deﬁnition of clinical failure. We recommend that further 
research should be done using an observational study of chil-
dren with non-severe pneumonia whose condition appears to 
be the same at day 2 to determine whether they actually require 
a change in therapy. Finally, close follow-up of all children is key 
to decreasing morbidity and mortality from pneumonia.  O
Acknowledgements
We thank Dr Roger Feldman for assistance in developing the 
informed consent procedure, Dr Mohammad Rahbar for sta-
tistical advice, and Dr Marcia Goldberg and Dr Juanita Hatcher 
for editorial help.
Funding: UNICEF, Pakistan. Cotrimoxazole (Septran) was pre-
pared and donated by Wellcome Pakistan Ltd, now Glaxo–Well-
come Pakistan. Glaxo–Wellcome Pakistan Ltd’s involvement in 
the study was limited exclusively to providing standard dose 
and double dose cotrimoxazole.
Conﬂicts of interest: none declared.
Résumé
Essai contrôlé randomisé comparant l’efﬁcacité d’une dose standard et d’une double dose de 
cotrimoxazole dans le traitement des pneumopathies infantiles au Pakistan
Objectif Les préoccupations grandissantes suscitées par la 
résistance bactérienne au cotrimoxazole, recommandé comme 
traitement de première intention par l’OMS pour faire face aux 
pneumopathies sans signe de gravité, ont conduit à penser qu’il 
ne s’agissait peut être pas du traitement optimal. Néanmoins, le 
passage à d’autres agents antimicrobiens, tels que l’amoxicilline, 
sera coûteux. Les auteurs ont comparé l’efﬁcacité clinique de 
l’administration bijournalière d’une dose standard et d’une double 
dose de cotrimoxazole dans le traitement des pneumopathies sans 
signe de gravité chez l’enfant.
Méthodes On a mis en œuvre un essai multicentrique contrôlé 
et randomisé dans sept consultations hospitalières externes et 
dans deux programmes de santé communautaire. On a attribué 
au hasard à 1143 enfants au total, âgés de 2 à 59 mois et atteints 
de pneumopathie sans signe de gravité, un traitement comprenant 
soit 4 mg de triméthoprime plus 20 mg de sulfaméthoxazole par 
kilogramme de poids corporel, soit 8 mg de triméthoprime plus 
40 mg de sulfaméthoxazole par kilogramme de poids corporel, 
par voie orale, deux fois par jour, pendant 5 jours. Il y avait échec 
thérapeutique lorsqu’un enfant nécessitait une modiﬁcation du 
traitement, mourrait ou était perdu de vue. Une modiﬁcation 
du traitement s’imposait chez les enfants dont l’état clinique 
se détériorait (apparition d’un tirage sous-costal ou de signes 
d’alerte) ou restait identique 48 h après le recrutement (c’est-à-dire 
que la différence entre les rythmes respiratoires mesurés lors du 
recrutement et 48 h après ne dépassait pas 5 respirations/minute).
Résultats On a analysé les résultats obtenus avec les 1134 
enfants, dont 578 avaient reçu une dose standard de cotrimoxazole 
et 556 une double dose. On a relevé un échec thérapeutique chez 
112 enfants (19,4 %) du groupe soumis au traitement standard et 
chez 118 enfants (21,2 %) du groupe recevant une double dose 
(risque relatif 1,10, intervalle de conﬁance à 95 % : 0,87 - 1,37). 
Une analyse multivariée a permis d’établir que le traitement avait 
une plus forte probabilité d’échouer chez les enfants auxquels on 
n’avait pas administré correctement le médicament (p = 0,001), 
chez les enfants de moins de 12 mois (p = 0,004), chez ceux ayant 
reçu auparavant des antibiotiques (p = 0,002), chez ceux dont le 
rythme respiratoire était supérieur ou égal à 20 respirations/minute 
et au point de coupure spéciﬁque à l’âge (p = 0,006) et chez ceux 
provenant de zones urbaines (p = 0,042).
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Resumen
Ensayo controlado aleatorizado de comparación de la dosis estándar y la dosis doble de cotrimoxazol 
contra la neumonía infantil en el Pakistán
Conclusion On a constaté une efficacité équivalente du 
cotrimoxazole sous forme de dose standard et de double dose dans 
le traitement des pneumopathies sans signe de gravité. Un suivi 
étroit des patients est essentiel pour prévenir toute aggravation 
de la maladie. L’échec clinique doit être déﬁni de manière plus 
spéciﬁque. La surveillance tant dans les zones rurales qu’urbaines 
est indispensable au développement de stratégies thérapeutiques 
reposant sur les résultats cliniques.
Objetivo La creciente preocupación en torno a la resistencia 
bacteriana al cotrimoxazol, producto recomendado por la OMS 
como medicamento de primera línea para tratar la neumonía 
no grave, ha llevado a pensar que ese tratamiento quizá no es 
el más adecuado. Sin embargo, sustituirlo por otros agentes 
antimicrobianos, como la amoxicilina, resulta costoso. Decidimos 
comparar la eﬁcacia clínica de la dosis estándar y la dosis doble 
de cotrimoxazol administrado dos veces al día como tratamiento 
de la neumonía no grave en los niños. 
Métodos Se llevó a cabo un ensayo multicéntrico controlado 
aleatorizado en siete departamentos ambulatorios de hospital 
y dos programas de salud comunitaria. Un total de 1143 niños 
de 2 a 59 meses con neumonía no grave fueron asignados al 
azar para recibir ya fuera 4 mg de trimetoprima más 20 mg de 
sulfametoxazol/kg de peso corporal o bien 8 mg de trimetoprima 
más 40 mg de sulfametoxazol/kg de peso corporal por vía oral 
dos veces al día durante 5 días. Se consideraron casos de fracaso 
terapéutico aquellos en los que el niño necesitaba un cambio de 
tratamiento, fallecía o se perdía en el seguimiento. Se decidía 
cambiar de tratamiento cuando la enfermedad se agravaba 
(aparecían tiraje torácico o signos de peligro) o permanecía 
estacionaria (se consideraba que así era cuando la frecuencia 
respiratoria no se desviaba más de 5 respiraciones/minuto de la 
que tenía el niño al entrar a participar en el estudio).
Resultados Se analizaron los resultados conseguidos en 1134 
niños: a 578 se les asignó la dosis ordinaria de cotrimoxazol, y a 
556 la dosis doble. El tratamiento fracasó en 112 niños (19,4%) 
en el grupo tratado de la forma habitual, y en 118 (21,2%) en el 
grupo sometido a la dosis doble (riesgo relativo: 1,10; intervalo 
de conﬁanza del 95% = 0,87–1,37). El análisis multifactorial 
reveló que el tratamiento tenía más probabilidades de fracasar 
entre los niños a los que no se les administraba correctamente el 
medicamento (P = 0,001), los menores de 12 meses (P = 0,004), 
los que habían usado antibióticos anteriormente (P = 0,002), los 
que presentaban una frecuencia respiratoria  20 respiraciones/
minuto por encima del umbral especíﬁco para la edad (P = 0,006) 
y los residentes en zonas urbanas (P = 0,042).
Conclusión El tratamiento estándar y la dosis doble de 
cotrimoxazol fueron igual de eﬁcaces en los casos de neumonía no 
grave. El seguimiento estrecho de los pacientes es esencial para 
prevenir el empeoramiento de la enfermedad.  Es preciso disponer de 
unas deﬁniciones de fracaso clínico más especíﬁcas. La vigilancia, 
tanto en las zonas rurales como en las urbanas, es esencial para poder 
formular políticas de tratamiento basadas en los resultados clínicos.
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Table 2. Univariate analysis of relation between treatment failure and signiﬁcant variables at baseline among 1134 children 
treated for non-severe pneumonia with either standard dose or double dose cotrimoxazole
Variable Total no.  Treatment  Treatment  Relative riska P-value 
  of children success (n = 904) failure (n = 230)
Strength of cotrimoxazole     
Double dose 556 438 118 1.10 (0.87–1.37) 0.461
Standard dose  578 446 112  
Median age in monthsb 1134 12 (6–22) 8 (4–18)  0.001
Mean age in monthsc 1134 15.7 (12.7) 13.7 (13.2)  0.032
Age categories      
 2–11 months 577 437 140 1.50 (1.19 –1.86) 0.001
 12–59 months 557 467 90  
History at baseline     
Median no. of days ill prior  1134 3 (2–5) 3 (2–5)  0.083 
 to presentationb
Mean duration of illnessc 1134 3.6 (2.8) 4.2 (3.7)  0.022
  < 3 days 456 379 77  
   3 days 678 525 153 1.33 (1.05–1.68) 0.020
Urban area 879 687 192 1.47 (1.08–1.95) 0.017
Cough 1083 867 216 0.73 (0.43–1.16) 0.211
Difﬁculty breathing 632 499 133 1.09 (0.86–1.36) 0.504
Fever 1002 797 205 1.09 (0.74–1.53) 0.731
Vomiting 300 243 57 0.92 (0.69–1.19) 0.558
Diarrhoea 201 157 44 1.10 (0.81–1.45) 0.562
Wheezing  3 times at any  45 33 12 1.33 (0.78–2.08) 0.262 
 time in the past 
Currently being breastfed  731 584 147 0.98 (0.76–1.23) 0.877
Tight chest binding  16 9 7 2.19 (1.12–3.41) 0.028
Any treatment in past 7 daysd 282 226 56 0.98 (0.74–1.26) 0.865
Documented antibiotic use 48 28 20 2.16 (1.47–2.92) 0.001 
 in past 7 days
Examination at baseline     
Wheezing 293 224 69 1.23 (0.96–1.56) 0.110
High respiratory ratee 117 83 34 1.51 (1.09 –2.00) 0.015
Malnourishedf 175 149 26 0.69 (0.47 –1.00) 0.052
Median weight-for-age scoreb 1128  –0.90 (–1.67 to –0.05)  –0.80 ( –1.55 to 0.00)  0.301
During the study     
Wheezing at any time  316 237 79 1.35 (1.06–1.69) 0.017 
 after enrolment
Was not given medicine  64 42 22 1.77 (1.21–2.43) 0.006 
 correctly
a  Values in parentheses are 95% conﬁdence intervals.
b  Values in parentheses are interquartile ranges.
c  Values in parentheses are standard deviations.
d  Deﬁned as treatment with antibiotics or other medicines.
e  A high respiratory rate was one in which the child had  20 breaths/minute above the age-adjusted WHO threshold for tachypnoea, that is  70 for children  
 aged 2–11 months and  60 for those aged 12–59 months.
f  Weight-for-age scores > 2 standard deviations below normal (15).
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Table 4. Characteristics of 1134 children treated for non-severe pneumonia, by study area
Variable Study areaa Relative riskb P-value
 Urban (n = 879) Rural (n = 255)
Treatment failure 192  (21.8) 38  (14.9) 1.45 (1.06–1.99) 0.017
Median age in monthsc  10  (5–18) 17  (7–26)  <0.001
Male  551  (63.0) 148  (58.0) 1.16 (0.93–1.44) 0.188
History at baseline    
Median no. of days ill prior to presentationc 3  (2–5) 2  (1–3)  <0.001
Fever 768  (87.4) 234  (91.8) 0.68 (0.45–1.02) 0.059
Cough 847  (96.4) 236  (92.5) 1.71 (1.18–2.48) 0.015
Difﬁculty breathing 515  (58.6) 117  (45.9) 1.48 (1.20–1.84) <0.001
Tight chest binding 14  (1.6) 2  (0.8) 1.81 (0.49–6.65) 0.546
Antibiotic use in past 7 days 43  (4.9) 5  (2.0) 2.21 (0.96–5.10) 0.050
Wheezing  3 times at any time in the past  23  (2.6) 22  (8.6) 0.44 (0.32–0.60) <0.001
Vomiting  250  (28.4) 50  (19.6) 1.48 (1.12–1.95) 0.005
Diarrhoea 166  (18.9) 35  (13.7) 1.35 (0.98–1.87) 0.062
Currently being breastfed 561  (63.8) 170  (66.7) 0.91 (0.72–1.14) 0.415
Any treatment in past 7 daysd 220  (25.0) 62  (24.3) 1.03 (0.80–1.33) 0.869
Examination at baseline    
High respiratory ratee  86  (9.8) 31  (12.2) 0.83 (0.60–1.15) 0.293
Wheezing  246  (28.0) 47  (18.4) 1.54 (1.16–2.06) 0.002
Malnutritionf 119  (13.6) 56  (22.0) 0.65 (0.51–0.84) 0.002
During the study    
Wheezing at any time during the study 263  (29.9) 53  (20.8) 1.47 (1.12–1.94) 0.004
Was not given medicine correctly 43  (4.9) 21  (8.2) 0.67 (0.46–0.96) 0.046
a  Values are numbers (percentages) unless otherwise indicated.
b  Values in parentheses in this column are 95% conﬁdence intervals.
c  Values in parentheses are interquartile ranges.
d  Deﬁned as treatment with antibiotics or other medicines.
e  A high respiratory rate was one in which the child had  20 breaths/minute above the age-adjusted WHO threshold for tachypnoea, that is  70 for children  
 aged 2–11 months and  60 for those aged 12–59 months.
f  Weight-for-age scores > 2 standard deviations below normal (15).
